FIELD: medicine.
SUBSTANCE: present invention relates to the field of diagnosing and treating oncological diseases, specifically to a compound having a structure
,
here M is 177Lu or 68Ga. Invention also relates to a medicinal agent and a therapeutic composition based on said compound.
EFFECT: invention provides high degree of capture and retention of diagnostic and therapeutic radioactive label selectively with respect to both primary and metastatic GRPR+ oncological disease.
6 cl, 8 dwg, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| GRPR ANTAGONISTS FOR DETECTING, DIAGNOSING AND TREATING GRPR-POSITIVE ONCOLOGICAL DISEASE | 2013 |
|
RU2693465C2 |
| RADIOPHARMACEUTICALS TARGETING GRPR AND THEIR USE | 2019 |
|
RU2798978C2 |
| BOMBESIN ANALOGUE PEPTIDE ANTAGONIST CONJUGATES | 2009 |
|
RU2523531C2 |
| RADIOLABELLED GRPR ANTAGONIST FOR USE AS THERAPEUTIC AND DIAGNOSTIC AGENT | 2020 |
|
RU2839888C1 |
| PARAMINOHYPURIC ACID (PAH) AS A KIDNEY PROTECTOR | 2020 |
|
RU2804349C2 |
| STABLE CONCENTRATED RADIOPHARMACEUTICAL COMPOSITION | 2020 |
|
RU2839656C1 |
| IMPROVED PEPTIDE GASTRIN-RELEASING COMPOUNDS | 2003 |
|
RU2330859C2 |
| RADIOPHARMACEUTICAL FOR THE DIAGNOSIS OF PROSTATE CANCER BY POSITRON EMISSION TOMOGRAPHY AND METHOD FOR ITS PRODUCTION | 2022 |
|
RU2796106C1 |
| A CONJUGATE CONTAINING A NEUROTENSIN RECEPTOR LIGAND AND ITS APPLICATION | 2015 |
|
RU2743781C2 |
| NEUROTENSIN RECEPTOR LIGANDS | 2013 |
|
RU2671970C2 |
Authors
Dates
2024-06-28—Published
2013-09-25—Filed